Arca
Skip to content
Tools
Tools

Fibromyalgia

Drug research and approvals for fibromyalgia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 142 studies of fibromyalgia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.

  • Recruiting worldwide: 142
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 142 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

4 approved, 15 in phase 3, 26 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Pregabalin, Milnacipran, Duloxetine, Levomilnacipran

Cyclobenzaprine
Phase 3 Serotonin 2a (5-HT2a) receptor antagonist
Esreboxetine
Phase 3 Norepinephrine transporter inhibitor
Mirogabalin
Phase 3 Voltage-gated calcium channel alpha2/delta subunit 1 modulator
Amitriptyline
Phase 3 Serotonin transporter inhibitor
Reboxetine
Phase 3 Norepinephrine transporter inhibitor
Oxybate
Phase 3 GABA-B receptor agonist
Gabapentin
Phase 3 Voltage-gated calcium channel modulator
Cannabidiol
Phase 3 Cannabinoid CB1 receptor negative allosteric modulator
Fluoxetine
Phase 3 Serotonin transporter inhibitor
Tramadol
Phase 3 Mu opioid receptor agonist
Lidocaine
Phase 3 Sodium channel alpha subunit blocker
Ketotifen
Phase 3 Histamine H1 receptor antagonist
Dolasetron
Phase 3 Serotonin 3a (5-HT3a) receptor antagonist
Memantine
Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
Erenumab
Phase 3 Calcitonin gene-related peptide type 1 receptor antagonist
Desvenlafaxine
Phase 2 Serotonin transporter inhibitor
Naltrexone
Phase 2 Opioid receptors; mu/kappa/delta antagonist
Dextromethorphan
Phase 2 Sigma opioid receptor agonist
Psilocybin
Phase 2 Serotonin 2a (5-HT2a) receptor agonist
Cannabinol
Phase 2
NYX-2925
Phase 2
Escitalopram
Phase 2 Serotonin transporter inhibitor
Metformin
Phase 2 Mitochondrial complex I (NADH dehydrogenase) inhibitor
Mirtazapine
Phase 2 Serotonin 2a (5-HT2a) receptor antagonist
Pyridostigmine
Phase 2 Acetylcholinesterase inhibitor
Ropinirole
Phase 2 D2-like dopamine receptor agonist
Droxidopa
Phase 2 Adrenergic receptor agonist
Carbidopa anhydrous
Phase 2 DOPA decarboxylase inhibitor
Cycloserine
Phase 2 D-alanylalanine synthetase inhibitor
Nabilone
Phase 2 Cannabinoid CB1 receptor agonist

Showing the 30 furthest along of 49 in trials.

How Its Trials Ended

1,156 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 201 whose ending is known, 62% met their primary endpoint, 7% missed it and 30% stopped early.

  • Completed, result not reported59952%
  • Ongoing20818%
  • Status unknown14813%
  • Met its primary endpoint12511%
  • Stopped: other or unclear393%
  • Missed its primary endpoint151%
  • Stopped: enrollment or feasibility61%
  • Stopped: sponsor or business decision50%
  • Stopped: funding50%
  • Stopped: lack of efficacy40%
  • Stopped: safety20%

Trials Authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Apr 5, 2022A randomized controlled trial of adjunctive d-cycloserine to intermittent theta-burst stimulation transcranial magnetic stimulation in fibromyalgiaCycloserineUniversity Of CalgaryClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.